TERNS PHARMACEUTICALS INC's ticker is TERN and the CUSIP is 880881107. A total of 45 filers reported holding TERNS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $2,169,000 | -32.0% | 874,600 | -18.6% | 0.09% | -5.2% |
| Q1 2022 | $3,192,000 | -52.5% | 1,074,834 | +13.2% | 0.10% | -70.8% |
| Q4 2021 | $6,715,000 | -16.8% | 949,834 | +22.6% | 0.33% | -46.3% |
| Q3 2021 | $8,074,000 | -15.1% | 774,834 | -0.1% | 0.62% | +19.1% |
| Q2 2021 | $9,513,000 | -41.5% | 775,934 | +3.2% | 0.52% | -62.1% |
| Q1 2021 | $16,275,000 | – | 751,813 | – | 1.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,099,309 | $13,015,819 | 9.59% |
| VR Adviser, LLC | 3,619,522 | $42,855,140 | 8.37% |
| Vivo Capital, LLC | 6,657,992 | $78,830,625 | 5.47% |
| Fairmount Funds Management LLC | 2,040,000 | $24,153,600 | 4.15% |
| Decheng Capital Management III (Cayman), LLC | 714,285 | $8,457,134 | 3.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 667,922 | $7,908,196 | 3.26% |
| Ikarian Capital, LLC | 721,341 | $8,540,677 | 1.94% |
| Orbimed Advisors | 7,619,135 | $90,210,558 | 1.77% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,448,275 | $40,827,576 | 1.72% |
| CROSSPOINT FINANCIAL, LLC | 12,054 | $142,719 | 1.54% |